Galectin Therapeutics Earnings Estimate

GALT Stock  USD 1.04  0.96  48.00%   
By analyzing Galectin Therapeutics' earnings estimates, investors can diagnose different trends across Galectin Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Galectin Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Galectin Therapeutics is projected to generate 0.0 in earnings per share on the 31st of December 2024. Galectin Therapeutics earnings estimates show analyst consensus about projected Galectin Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Galectin Therapeutics' historical volatility. Many public companies, such as Galectin Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Galectin Therapeutics' earnings estimates, investors can diagnose different trends across Galectin Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to drop to about (34.6 K) in 2024
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Galectin Therapeutics Earnings per Share Projection vs Actual

About Galectin Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Galectin Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Galectin Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Galectin Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-354.4 M-336.7 M
Retained Earnings Total Equity-216 M-226.8 M
Earnings Yield(0.41)(0.43)
Price Earnings Ratio(2.43)(2.55)
Price Earnings To Growth Ratio(0.20)(0.21)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.